|
xeloda should hold no weight in whether to dose tdm1.
dosing depends on which trial you are attempting to get into..
the p2 taxotere vs tdm1.. for first line treatment or
the pivotal p3 currently .. emilia.. tdm1 vs tyk/xel for second line treatment..
these trials will be semi-muted.. because tdm1 will be approved based on the recently finished p2 trial for 3rd line treatment.. after patients failed tykerb/xeloda.. genentech antipates filing for approval in q1 2010, with approval by fall 2010, or in the next 15 months.
|
Hybrid Mode
